Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 25, 2021 at 11:26 am
Share
Zhejiang Xinguang Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 159.502 million compared to CNY 128.431 million a year ago. Operating income was CNY 67.007 million compared to CNY 52.853 million a year ago. Net income was CNY 57.015 million compared to CNY 46.020 million a year ago. Basic earnings per share from continuing operations was CNY 0.36 compared to CNY 0.29 a year ago.
Zhejiang Xinguang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of Chinese patent medicines, chemical medicines and health foods. The Company's main products are Huangqishengmaiyin, Shenjindan Capsules, American Ginseng Oral Liquid and other products. The treatment scope is mainly cardiovascular and cerebrovascular diseases, trauma diseases, and covers respiratory system, digestive system, urinary system, pediatric diseases and improving immunity. The Company operates its businesses mainly in domestic markets, with Zhejiang Province as its major market.